PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!
PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!

Google Search

Showing posts with label Shows. Show all posts
Showing posts with label Shows. Show all posts

Sunday, June 15, 2014

Herpes Shows Up Like a Missionary

Herpes shows up like a missionary -- completely unexpected and completely inconvenient. Like said missionary, herpes stops by to warn how dangerously you lead your life. But, really, you know Goddess sent them here to punish you. That's because when either knocks at your door, you've gotta dump all of your immediate plans and figure out how to get rid of the damn nuisance.

The first hateful bump showed up on a Thursday afternoon; it was a slow day. By 3 p.m. I hadn't even had sex! On a good day I'll have sex at least once. On a great day my penis will be pleasured by three or four men; often at the same time. Only on the worst days am I forced to endure a whole 24 hours with no sexual contact. I hate those days, because they make me feel like an unattractive failure.

In addition to being a failure, I'm also fairly stupid, so that's why I thought the angry red knots were pimples that had migrated south for winter. Within a few hours I realized that two of my favorite activities, bicycling and masturbating, were tediously painful. Every stroke made the intruders angrier, and by Thursday night I realized I wasn't dealing with garden variety pimples. I asked my doctor, WebMD, what was wrong. She was clear and professional: I probably had herpes. And based on the accompanying literature she suggested, I knew what she really wanted to say: And I'm not surprised, you slut.

I was convinced the Goddess I didn't believe in had sent herpes as a punishment. As the hateful bumps hardened and blistered over, now more itchy than painful, I knew I should have listened to those missionaries she sent to me. I should have took pleasure in the divine word of Goddess instead of pleasuring her innocent messengers. I should have learned the lessons of the bible instead of learning how to seduce beautiful, clean-cut boys who show up on my doorstep. I probably required a lifetime of prescribed rituals to overcome my sins, and I was not enthralled by the prospect.

For all these shortcomings, I turned to the Goddess I didn't believe in and prayed. I asked her for forgiveness, as well as relief from this curse. Only hours after my prayer, Goddess sent a dermatologist to a dinner party I was at. Covertly in the bathroom, I pulled down my pants for this guardian angel doctor. He poked and prodded at my hateful sores. Doctor Angel gave me dreadful news: You have ingrown pubic hairs, not herpes.

The Goddess I didn't believe in had sent me a message. She wanted me to change my life, and she wanted me to learn from this little crisis. Goddess took away my sexual privileges for several bumpy days, but I managed to survive without my usual empty intercourse. The true test of life is if you can slow down and enjoy what Goddess sends you -- the good, the bad, and the embarrassing.


View the original article here

Monday, December 16, 2013

HerpV: Genital Herpes Vaccine Shows Promise


Nov 7 (Reuters) - Agenus Inc said a trial of its experimental genital herpes vaccine reduced the rate at which patients released the virus, reducing the likelihood of infecting others, sending its shares up 32 percent in premarket trading.

The 15 percent reduction in the release of the virus by patients receiving the vaccine in a mid-stage trial compared to those on a placebo, who showed no reduction.

The vaccine, HerpV, also reduced the severity of the infection by 34 percent.

The mid-stage trial had 80 patients with a history of 1-9 herpes recurrences within the prior 12 months. Of them, 70 received the vaccine and 10 received placebo, Agenus said in a statement.

HerpV, being developed as an "off-the-shelf" vaccine, contains Agenus's QS-21 Stimulon adjuvant that boosts specific immune responses.

The trial tested the efficacy of the vaccine by measuring the release of the virus by patients 45 days before and after three injections of HerpV. A majority of the patients also received a booster injection, given 6 months after the first vaccination.

Genital herpes, a highly contagious sexually transmitted infection, is usually caused by the herpes simplex virus (HSV). There are two types of HSV and Agenus's vaccine targets HSV type 2, which most often causes genital herpes.

According to the U.S. Centers for Disease Control and Prevention, 776,000 people in the United States get new herpes infections annually and one out of six people aged 14 to 49 years has genital HSV-2 infection.

Agenus said it expected more data in the first half of 2014, showing how the patients fared after the booster shots.

The company's partners are also testing the QS-21 Stimulon adjuvant in combination with other vaccines.

Agenus shares were up at $3.16 in trading before the bell. The stock closed at $2.40 on Wednesday on the Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty and Kirti Pandey)


View the original article here

Friday, June 28, 2013

Rihanna Herpes and Lipstick Fiasco Shows Need for Effective Herpes Remedy; polyDNA Recommends Gene-Eden-VIR to Kill ...

Rochester, NY (PRWEB) June 11, 2013

The National Health Service website says that “It is not possible to prevent becoming infected with the herpes simplex virus or to prevent outbreaks of cold sores.” (1) In fact, there are many ways that oral herpes (HSV-1) can be transmitted. Even a shared tube of lipstick can be a method of herpes transmission. (2) That’s why people need a remedy that can help their immune system kill the virus once it enters the body.

For example, 28 year old Starkeema Greenridge of Harlem could have used such a remedy when she “was infected by the virus when she sampled a lipstick offered by one of the singer's sponsors.”(The Guardian, May 31, 2013) (3)

"If a woman has a cut on her lip and borrows lipstick from someone who has a cold sore, she'll get a cold sore. You can pass herpes [the cold sore virus], conjunctivitis [pink eye] and all sorts of things through sharing makeup," - Dr. Zein Obagi (Los Angeles Times, 2010) (4)

Another doctor noted that “direct contact with a herpes lesion, engaging in sexual activity with an actively infected person or sharing a drinking glass, lipstick or cigarette with a person with an active herpes outbreak on their mouth could transmit the disease.” (Dr. Joy M. Jackson, Healthtap.com) (5)

“Since oral herpes spreads so easily, people need protection. I recommends Gene-Eden-VIR.” – Mike Evans, polyDNA

Gene-Eden-VIR is a natural dietary supplement that helps the immune system kill the herpes virus. polyDNA recommends that people who want to protect themselves against the herpes virus or are already infected take Gene-Eden-VIR.

Gene-Eden-VIR is designed to fight the latent herpes virus. A recent post marketing clinical study showed that Gene-Eden-VIR is safe and effective. Up to 70% of those studied reported a decrease in herpes symptoms. (6)

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes. (7)

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1)    http://articles.latimes.com/2010/apr/18/image/la-ig-testers-20100418
(2)    http://www.nhs.uk/Conditions/Cold-sore/Pages/Prevention.aspx
(3)    http://www.guardian.co.uk/music/2013/may/31/rihanna-lipstick-gave-me-herpes
(4)    http://articles.latimes.com/2010/apr/18/image/la-ig-testers-20100418
(5)    https://www.healthtap.com/topics/can-you-get-herpes-from-sharing-lipstick
(6)    cbcd.net/Gene-Eden-VIR-Clinical-Study.php
(7)    gene-eden-kill-virus.com/studies.php

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.



View the original article here

Sunday, May 12, 2013

How to Prevent Genital Herpes? polyDNA’s Monthly Survey Shows an Ignorant Public

polyDNA recommends using Gene-Eden-VIR to protect against genital herpes.


Rochester, NY (PRWEB) April 17, 2013

polyDNA’s monthly survey shows that many in the public are unaware of the recommended ways of preventing genital herpes.

In the open comments section of the survey, a typical response was offered by Shari C. from Raleigh, N.C. “I have been dating a really great guy who recently told me he has herpes (got it from his ex-wife). I don't have herpes and I don't a lot about STDs. It’s scary because I have no clue how to protect myself from herpes except for what you always hear. You know, have your man wear a condom.”


This ignorance is an important issue since, “Nationwide, 16.2%, or about one out of six, people aged 14 to 49 years have genital HSV-2 infection.” (1) Moreover, “Most individuals infected with HSV-1 or HSV-2 experience either no symptoms or have very mild symptoms that go unnoticed or are mistaken for another skin condition.”(1) Yet, these people can still infect their partners.


According to the CDC, there are three methods of herpes prevention. (1) These methods include the use of condoms, abstention from sexual contact, and having sex only within a committed, monogamous relationship.


polyDNA would like to recommend a fourth way of genital herpes prevention, which has unique advantages. This method reduces the risk of having sex with an infected individual. In addition, it provides protection against other viruses such as HPV.


That method is taking the antiviral, dietary supplement, Gene-Eden-VIR.


“The key to your health is to reduce the level of the latent viruses in your body to harmless levels.” – Dr. Hanan Polansky


A recent post marketing clinical study showed that Gene-Eden-VIR is effective against the latent herpes virus. By helping the body's immune system target the latent herpes virus, people also lower their risk of developing genital herpes symptoms. (2)


Gene-Eden-VIR is highly effective against the latent herpes virus. Each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2. (3)


To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.


References:


(1) http://www.cdc.gov/std/herpes/stdfact-herpes.htm


(2) http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php


(3) http://www.gene-eden-kill-virus.com/studies.php


###


polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.


In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.


polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.


View the original article here

Tuesday, April 2, 2013

Oral Herpes Spread Through Kissing? polyDNA’s Monthly Survey Shows Segment of Public Believes Kissing with Fever ...

Survey Shows 45% of Respondents Believe Kissing with Oral Herpes Lesions “Ok”

Rochester, NY (PRWEB) March 28, 2013

polyDNA recently received answers to its monthly survey regarding the public's knowledge of the herpes virus.

One of the questions asked was, "If you have cold sores, do you think it is possible to infect others while kissing?" Amazingly, a significant percentage of the public said "No."

“If you have this sore on your lip or whatever, and it’s going away, well then it’s going away, right? Nobody wants to kiss you when you have a nasty, open cold sore where everyone can see it, but when it’s on the way out? Your body killed it, you know. It’s gone. You ain’t going to spread it to nobody.” –Shauna B., Charlotte, N.C.

The truth is exactly the opposite however. polyDNA’s survey found that the respondents did not realize that, “The virus is spread from person to person by kissing, by close contact with herpetic lesions, or even from contact with apparently normal skin that is shedding the virus. Infected saliva is a common means of virus transmission.” [1]

Additionally, the respondents had no clue that, “About 50 percent to 80 percent of US adults have oral herpes. According to the National Institutes of Health (NIH), by age 50, approximately 90 percent of adults have been exposed to the virus…The herpes lesions typically last a week to 10 days and most often occur around the lips, oral mucosa, and/or tongue.” [2]

Mike Evans, from the polyDNA said, "It's amazing. The very idea that so many people have no real clue as to how oral herpes is transmitted is incredible. The fact is though, the majority just doesn’t know."

polyDNA believes that because of the ignorance revealed in its survey, the public should be aware of the relationship between kissing and the spread of oral herpes (HSV-1). In addition, the biotechnology firm recommends boosting the immune system against a latent herpes infection through the use of a scientific, all natural remedy. That remedy is Gene-Eden-VIR.

A recent post marketing clinical study showed that Gene-Eden-VIR is effective against the latent herpes virus. By helping the body's immune system target the latent herpes virus, people also lower their risk of developing fever blisters, cold sores, or genital herpes symptoms. [3]

Gene-Eden-VIR is highly effective against the latent herpes virus, each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2. [4]

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com.

References:

[1] [2[3 [4 http://www.gene-eden-kill-virus.com/studies.php


polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis
PolyDNA
5852509999
Email Information


View the original article here

Monday, August 27, 2012

Microbicide gel: Reduced risk of HIV and herpes infections in women, study shows

ScienceDaily (July 20, 2010) — Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the XVIII International AIDS Conference in Vienna, Austria.

The microbicide containing 1% tenofovir -- an antiretroviral drug widely used in the treatment of HIV -- was found to be 39% effective in reducing a woman's risk of becoming infected with HIV during sex and 51% effective in preventing genital herpes infections in the women participating in the trial. Should other studies of tenofovir gel confirm these results, widespread use of the gel, at this level of protection, could prevent over half a million new HIV infections in South Africa alone over the next decade.

"Tenofovir gel could fill an important HIV prevention gap by empowering women who are unable to successfully negotiate mutual faithfulness or condom use with their male partners," said study co- principal investigator, Dr. Quarraisha Abdool Karim, Associate Director of CAPRISA and Associate Professor of Epidemiology at Columbia University. "This new technology has the potential to alter the course of the HIV epidemic, especially in southern Africa where young women bear the brunt of this devastating disease."

Tenofovir works by preventing HIV from growing inside human cells. Taken in pill form, tenofovir is a common component of various three-drug cocktails that are used to treat HIV infections. The new results now indicate that tenofovir formulated as a topical gel and inserted into the female genital tract also has great promise for use in HIV and herpes simplex virus type-2 (HSV-2) prevention.

The CAPRISA 004 trial of tenofovir gel involved 889 women at high risk of HIV infection at an urban and a rural site in KwaZulu-Natal, South Africa. Overall, 98 women out of the 889 became HIV positive during the trial -- with 38 in the tenofovir gel group and 60 in the placebo gel group. Out of the 434 women who tested negative for herpes at the start of the trial, 29 became infected in the tenofovir group and 58 became infected in the placebo group. The reduced rates of HIV and herpes infections among the women who used the tenofovir gel are statistically significant.

"Tenofovir gel has a potential dual effect in preventing HIV. Since women with genital herpes are much more likely to become infected with HIV, the additional protection of tenofovir gel against herpes creates a second mechanism whereby the gel may have a bigger impact in preventing HIV," said study co-principal investigator, Dr Salim S. Abdool Karim, Director of CAPRISA and Pro Vice-Chancellor (Research) of the University of KwaZulu-Natal, South Africa. "The trial results are a significant first step toward establishing the effectiveness of antiretroviral drugs for HIV and genital herpes prevention; confirmatory studies are now urgently needed."

During monthly visits, all participants were provided with HIV risk-reduction counseling, condoms and treatment for sexually transmitted infections, and each was clinically examined for potential side effects and tested for HIV infection. The study was double-blinded and neither the researchers nor the participating women knew whether a woman in the study received tenofovir gel or placebo gel. Women in the study were advised to use the gel up to 12 hours before sex and soon after having sex for a maximum of two doses in 24 hours -- a dosing strategy referred to as BAT24. Participants used the gel for a minimum of one year and a maximum of two and a half years. The trial team observed no substantive safety concerns from use of the gel. Further, no increase in risky behavior was observed in the women.

The CAPRISA researchers also found that the protective effect against HIV and genital herpes increased as use of the tenofovir gel increased. Women who used the gel in more than 80% of their sex acts had a 54% reduction in HIV infections, whereas those who used the gel in less than half of their sex acts had a 28% reduction in HIV infections. Among those women who became infected, tenofovir gel had no effect on the amount of HIV in their bloodstream at the time of infection. Also, none of the women who became infected with HIV showed resistance to tenofovir.

All volunteers to the study who tested HIV positive were provided care including ARV treatment at the CAPRISA clinics and women who became infected during the study were enrolled into CAPRISA studies and/or the CAPRISA AIDS treatment program at their respective sites for ongoing care and support.

This study was jointly funded by the Governments of South Africa and the United States, through the Technology Innovation Agency (TIA) and the US Agency for International Development (USAID), respectively. USAID provided $16.5M and TIA provided $1.1 for the study. "USAID is proud to be the major donor of this first-ever proof of concept that a vaginal microbicide can effectively and safely reduce the risk of HIV transmission from men to vulnerable women. The success of the CAPRISA 004 trial perfectly complements the Global Health Initiative and our focus on women's health, both in prevention and sustainable health delivery systems," stated USAID Administrator Raj Shah.

The promising findings of the CAPRISA 004 study is only a first step in determining if tenofovir gel is effective in preventing HIV and herpes infection; additional studies are urgently needed to confirm and extend the findings of the CAPRISA study. Important information is expected from current studies such as the Microbicide Trials Network's VOICE study, which is currently assessing daily tenofovir gel as well as daily tenofovir and Truvada tablets in women in several African countries. Studies of daily Truvada tablets are underway in intravenous drug users, young high-risk women and men who have sex with men.

"We are proud to have partnered with CAPRISA and CONRAD on this important study. We see it as a major victory in the field of HIV prevention research. This is the first evidence that an antiretroviral drug in a gel form -- a microbicide -- can reduce HIV and genital herpes infection in women," said Ward Cates, President of FHI. "The next step is to see whether other studies underway confirm these exciting results."

Only after drug regulatory authorities determine that tenofovir gel is safe and effective for HIV prevention, can the gel be made available to the public for HIV prevention. Since this process can take several years, TIA and U.S.-based CONRAD are working together to address the challenges to making the gel available first to women in South Africa.

"CONRAD has given the rights to manufacture this gel to the government of South Africa to get this much needed product to women in South Africa as rapidly as possible," said Dr. Henry Gabelnick, Executive Director of CONRAD, who provided the gel for the study. "The Technology Innovation Agency (TIA) is working closely with the South African government, CAPRISA and CONRAD to ensure that this important innovation makes an impact in preventing the spread of HIV/AIDS," said Dr. Mamphela Ramphele, Chairperson of TIA.

Ambassador Eric Goosby, U.S. Global AIDS Coordinator said, "The results of the CAPRISA trial provide new hope and direction for not only HIV prevention, but also broader efforts under the Global Health Initiative. We recognize that microbicides will be a great asset to HIV prevention efforts, and the U.S. Government is pleased to support this important research."

Professor Malegapuru Makgoba, Vice-Chancellor of the University of KwaZulu-Natal stated, "This piece of research is a significant milestone for women in the thirty year history of the HIV/AIDs epidemic, microbicides and antiretroviral research. The research represents that which is best in science with direct translation into prevention policy, bringing a message of hope and empowerment to women, policymakers and scientists. These research findings will not only significantly alter the shape and form but also the future direction of this devastating epidemic."

"The trial's findings create a new vision for the opportunity for prevention of HIV and re-define the public health approach to HIV control," added Dr Linda Fried, Dean of the Mailman School of Public Health of Columbia University, New York.

The trial was conducted by CAPRISA in partnership with the U.S.-based organizations FHI and CONRAD with funding from USAID. Gilead Sciences donated the active ingredient for the manufacture of the tenofovir gel.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by CONRAD, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Sunday, April 15, 2012

Microbicide gel: Reduced risk of HIV and herpes infections in women, study shows

ScienceDaily (July 19, 2010) — Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the XVIII International AIDS Conference in Vienna, Austria.

The microbicide containing 1% tenofovir -- an antiretroviral drug widely used in the treatment of HIV -- was found to be 39% effective in reducing a woman's risk of becoming infected with HIV during sex and 51% effective in preventing genital herpes infections in the women participating in the trial. Should other studies of tenofovir gel confirm these results, widespread use of the gel, at this level of protection, could prevent over half a million new HIV infections in South Africa alone over the next decade.

"Tenofovir gel could fill an important HIV prevention gap by empowering women who are unable to successfully negotiate mutual faithfulness or condom use with their male partners," said study co- principal investigator, Dr. Quarraisha Abdool Karim, Associate Director of CAPRISA and Associate Professor of Epidemiology at Columbia University. "This new technology has the potential to alter the course of the HIV epidemic, especially in southern Africa where young women bear the brunt of this devastating disease."

Tenofovir works by preventing HIV from growing inside human cells. Taken in pill form, tenofovir is a common component of various three-drug cocktails that are used to treat HIV infections. The new results now indicate that tenofovir formulated as a topical gel and inserted into the female genital tract also has great promise for use in HIV and herpes simplex virus type-2 (HSV-2) prevention.

The CAPRISA 004 trial of tenofovir gel involved 889 women at high risk of HIV infection at an urban and a rural site in KwaZulu-Natal, South Africa. Overall, 98 women out of the 889 became HIV positive during the trial -- with 38 in the tenofovir gel group and 60 in the placebo gel group. Out of the 434 women who tested negative for herpes at the start of the trial, 29 became infected in the tenofovir group and 58 became infected in the placebo group. The reduced rates of HIV and herpes infections among the women who used the tenofovir gel are statistically significant.

"Tenofovir gel has a potential dual effect in preventing HIV. Since women with genital herpes are much more likely to become infected with HIV, the additional protection of tenofovir gel against herpes creates a second mechanism whereby the gel may have a bigger impact in preventing HIV," said study co-principal investigator, Dr Salim S. Abdool Karim, Director of CAPRISA and Pro Vice-Chancellor (Research) of the University of KwaZulu-Natal, South Africa. "The trial results are a significant first step toward establishing the effectiveness of antiretroviral drugs for HIV and genital herpes prevention; confirmatory studies are now urgently needed."

During monthly visits, all participants were provided with HIV risk-reduction counseling, condoms and treatment for sexually transmitted infections, and each was clinically examined for potential side effects and tested for HIV infection. The study was double-blinded and neither the researchers nor the participating women knew whether a woman in the study received tenofovir gel or placebo gel. Women in the study were advised to use the gel up to 12 hours before sex and soon after having sex for a maximum of two doses in 24 hours -- a dosing strategy referred to as BAT24. Participants used the gel for a minimum of one year and a maximum of two and a half years. The trial team observed no substantive safety concerns from use of the gel. Further, no increase in risky behavior was observed in the women.

The CAPRISA researchers also found that the protective effect against HIV and genital herpes increased as use of the tenofovir gel increased. Women who used the gel in more than 80% of their sex acts had a 54% reduction in HIV infections, whereas those who used the gel in less than half of their sex acts had a 28% reduction in HIV infections. Among those women who became infected, tenofovir gel had no effect on the amount of HIV in their bloodstream at the time of infection. Also, none of the women who became infected with HIV showed resistance to tenofovir.

All volunteers to the study who tested HIV positive were provided care including ARV treatment at the CAPRISA clinics and women who became infected during the study were enrolled into CAPRISA studies and/or the CAPRISA AIDS treatment program at their respective sites for ongoing care and support.

This study was jointly funded by the Governments of South Africa and the United States, through the Technology Innovation Agency (TIA) and the US Agency for International Development (USAID), respectively. USAID provided $16.5M and TIA provided $1.1 for the study. "USAID is proud to be the major donor of this first-ever proof of concept that a vaginal microbicide can effectively and safely reduce the risk of HIV transmission from men to vulnerable women. The success of the CAPRISA 004 trial perfectly complements the Global Health Initiative and our focus on women's health, both in prevention and sustainable health delivery systems," stated USAID Administrator Raj Shah.

The promising findings of the CAPRISA 004 study is only a first step in determining if tenofovir gel is effective in preventing HIV and herpes infection; additional studies are urgently needed to confirm and extend the findings of the CAPRISA study. Important information is expected from current studies such as the Microbicide Trials Network's VOICE study, which is currently assessing daily tenofovir gel as well as daily tenofovir and Truvada tablets in women in several African countries. Studies of daily Truvada tablets are underway in intravenous drug users, young high-risk women and men who have sex with men.

"We are proud to have partnered with CAPRISA and CONRAD on this important study. We see it as a major victory in the field of HIV prevention research. This is the first evidence that an antiretroviral drug in a gel form -- a microbicide -- can reduce HIV and genital herpes infection in women," said Ward Cates, President of FHI. "The next step is to see whether other studies underway confirm these exciting results."

Only after drug regulatory authorities determine that tenofovir gel is safe and effective for HIV prevention, can the gel be made available to the public for HIV prevention. Since this process can take several years, TIA and U.S.-based CONRAD are working together to address the challenges to making the gel available first to women in South Africa.

"CONRAD has given the rights to manufacture this gel to the government of South Africa to get this much needed product to women in South Africa as rapidly as possible," said Dr. Henry Gabelnick, Executive Director of CONRAD, who provided the gel for the study. "The Technology Innovation Agency (TIA) is working closely with the South African government, CAPRISA and CONRAD to ensure that this important innovation makes an impact in preventing the spread of HIV/AIDS," said Dr. Mamphela Ramphele, Chairperson of TIA.

Ambassador Eric Goosby, U.S. Global AIDS Coordinator said, "The results of the CAPRISA trial provide new hope and direction for not only HIV prevention, but also broader efforts under the Global Health Initiative. We recognize that microbicides will be a great asset to HIV prevention efforts, and the U.S. Government is pleased to support this important research."

Professor Malegapuru Makgoba, Vice-Chancellor of the University of KwaZulu-Natal stated, "This piece of research is a significant milestone for women in the thirty year history of the HIV/AIDs epidemic, microbicides and antiretroviral research. The research represents that which is best in science with direct translation into prevention policy, bringing a message of hope and empowerment to women, policymakers and scientists. These research findings will not only significantly alter the shape and form but also the future direction of this devastating epidemic."

"The trial's findings create a new vision for the opportunity for prevention of HIV and re-define the public health approach to HIV control," added Dr Linda Fried, Dean of the Mailman School of Public Health of Columbia University, New York.

The trial was conducted by CAPRISA in partnership with the U.S.-based organizations FHI and CONRAD with funding from USAID. Gilead Sciences donated the active ingredient for the manufacture of the tenofovir gel.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by CONRAD, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Monday, October 31, 2011

Herpes Virus Shows Early Promise In Treating Triple-Negative Breast Cancer

Oncolytic viral therapy shows great potential
for treating an aggressive form of breast cancer

Newswise — SAN FRANCISCO: Researchers from Memorial Sloan-Kettering Cancer Center in New York City report they have successfully treated triple-negative breast cancer (TNBC) in petri dishes and in mouse models with a method based upon a herpes simplex virus. The study on the viral-based therapy was reported today at the 2011 Annual Clinical Congress of the American College of Surgeons.

Triple-negative breast cancer is an aggressive type of breast cancer that can account for up to 20 percent of all cases and is responsible for a disproportionate number of breast cancer deaths, according to the researchers. Moreover, the disease is most likely to surface in younger women (< 35 years old), especially if they are African American or Hispanic.

Because these types of cancerous tumors do not express the estrogen receptor, progesterone receptor, or HER-2 receptor, found in other more common types, newer targeted therapies such as tamoxifen and Herceptin are ineffective against the disease.

“Triple-negative breast cancer patients are in dire need of targeted therapies,” according to Sepideh Gholami, MD, a research fellow in the laboratory of Yuman Fong, MD, FACS, at Memorial Sloan-Kettering Cancer Center. “Although these tumors respond to a variety of chemotherapies, they have a high recurrence and metastatic rate.”

In the study, Dr. Gholami and her colleagues examined TNBC cell lines and infected them with a herpes simplex virus called NV1066. After treatment with the virus, more than 90 percent cell kill was achieved in all cell lines within a week. Furthermore, the researchers injected TNBC cells into laboratory mice. After treating the mouse models with the virus, and measuring the change in the tumors over 20 days, they found that the tumors had largely disappeared.

It was very surprising to see such an intense response. “The difference was dramatic, because sometimes we can stop tumor growth and achieve tumor regression,” Dr. Gholami said. “Our results are very exciting because we may be coming up with an approach that could potentially exploit the unique vulnerabilities of these specific cancer cells.”

Moreover, Dr. Gholami explained that TNBC cells have high levels of p-MAPK, a protein that promotes cancer cells to grow and has been reported as a potential cause for resistance to current conventional therapies. Knowing that the herpes virus specifically targets cells that over express this protein is the reason she chose to test this treatment protocol. “When we infect TNBC cells with the herpes virus and measure p-MAPK levels, the protein level decreases with time after treatment with the virus,” Dr. Gholami said.

The hope is that advances in oncolytic viral therapy, which uses viruses tailored to target and destroy cancer cells while sparing healthy cells, will allow researchers to develop more effective strategies for hard-to-treat cancers. A similar herpes virus has been tested in clinical trials against head and neck cancers. But this is the first laboratory study to show promise in using the therapy to treat TNBC.

The next steps, Dr. Gholami said, are to map out the pathways in which the virus kills the tumor cells to determine how to improve upon this mechanism. In the future, the Fong laboratory, which is on the forefront in oncolytic viral therapy research, will continue this avenue of investigation in animal studies. The team will also work to identify leads to understand what existing chemotherapy drugs can be used synergistically with this viral therapy. Finding complementary treatments that kill fast-growing cancer cells and combat resistance is the key to possibly making a cure a reality.

If additional animal studies are also positive, human clinical trials could be on the horizon. “Our goal is to improve this version of the virus and get it into a clinical trial,” Dr. Gholami said. “Ultimately, I believe the treatment for TNBC will be a multimodality targeted treatment approach: potentially using a viral-based therapy plus some other targeted chemotherapy or radiation.”

The study was supported by grants from the National Institutes of Health and the Flight Attendant Medical Research Institution.

Other participants in the study include Chun-Hao Chen, MD; Sizhi Paul Gao, MD, PhD; Joshua Carson, MD, PhD; Taejin Song, MD, PhD, FACS; Jackie Bromberg, MD, PhD; and Yuman Fong, MD, FACS.




View the original article here